Laboratory monitoring of the non-vitamin K oral anticoagulants

Journal of the American College of Cardiology

Volumn 64, Issue 11, 2014, Pages 1140-1142

  Blann, Andrew D ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Apixaban; Coagulation tests; Dabigatran; Monitoring; Non vitamin K oral anticoagulant (NOAC); Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN; EDOXABAN; NON VITAMIN K ORAL ANTICOAGULANT AGENT; RIVAROXABAN; UNCLASSIFIED DRUG; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; DRUG MONITORING; ECARIN CLOTTING TIME; HUMAN; LABORATORY TEST; NOTE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SENSITIVITY AND SPECIFICITY; THROMBIN TIME; ANALOGS AND DERIVATIVES;

ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; DRUG MONITORING; FACTOR XA INHIBITORS; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; THIOPHENES;

EID: 84922393444     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.07.010     Document Type: Editorial

References (12)

1. De Caterina R, Husted S, Wallentin L, et al. European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. General mechanisms of coagulation and targets of anticoagulants (section I). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;109:569-79.
2. Husted S, de Caterina R, Andreotti F, et al. ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost 2014;111:781-2.
3. Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulation intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Society for Standards in Haematology. Br J Haematol 2012;159:427-9.
4. Huisman MV, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012;107:838-47.
5. Samama MM, Contant G, Spiro TE, et al. Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012;107:379-87.
6. Turpie AG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2012;108:876-86.
7. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011;9:133-9.
8. Douxfils J, Dogné JM, Mullier F, et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013;110:543-9.
9. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
10. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51.
11. Cushman M, Lim W, Zakai NA. Clinical Practice Guide on Antithrombotic Drug Dosing and Management of Antithrombotic Drug-Associated Bleeding Complications in Adults (February 2014). Available at: http://www.hematology.org/Clinicians/Guidelines-Quality/Quick-Ref/2869.aspx. Accessed July 16, 2014.
12. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014;64: 1128-39.